Allogeneic cell therapy and oncology research by Allogene Therapeutics
Allogene Therapeutics presents interim futility analysis for ALPHA3 at SITC2026
Allogene Therapeutics announced an interim futility analysis for its ALPHA3 allogeneic CART cell therapy program during SITC2026. The company also outlined the continued expansion of its ...
Allogene Therapeutics advances early LBCL intervention with integrated ALPHA3 trial
Allogene Therapeutics is integrating investigational minimal residual disease (MRD) testing technology with its off-the-shelf CAR T cell therapy in the ALPHA3 trial targeting large B-cell lymphoma ...
Allogene Therapeutics to present pipeline and strategy updates at fall investor conferences
Allogene Therapeutics will participate in a series of fall investor conferences, where the company plans to deliver updates on its investigational pipeline and outline its corporate strategy. ...
Allogene Therapeutics advances cell therapy pipeline in latest business update
Allogene Therapeutics has published its corporate update for the second quarter of 2026, outlining recent business advances. The update includes progress in its allogeneic CAR-T and cell therapy ...
Allogene Therapeutics tests new 1L consolidation to predict relapse risk in LBCL treatment
Allogene Therapeutics is evaluating a first-line (1L) consolidation approach aimed at predicting and potentially preventing relapse in large B-cell lymphoma (LBCL) patients after frontline ...
FDA designations accelerate Allogene Therapeutics progress on allogeneic CAR-T for LBCL
Allogene Therapeutics has announced that the U.S. Food and Drug Administration has granted both RMAT and Fast Track designations to its investigational, off-the-shelf allogeneic CAR-T product, ...
Allogene Therapeutics studies new 1L consolidation to prevent LBCL relapse
Allogene Therapeutics is investigating a novel first-line (1L) consolidation approach aimed at predicting and potentially preventing relapse in patients with large B-cell lymphoma (LBCL) following ...
Allogene Therapeutics pursues early cancer relapse detection in LBCL with ALPHA3 trial integrating MRD testing
One in three patients with large B-cell lymphoma (LBCL) experience cancer recurrence after receiving first-line treatment, according to Allogene Therapeutics. The company is advancing its ALPHA3 ...
Allogene Therapeutics advances ALPHA3 trial data to expand off the shelf CAR T access
Allogene Therapeutics has released early results from its ALPHA3 trial, highlighting progress in developing investigational off the shelf CAR T therapy for patients with large B cell lymphoma ...
Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations
Allogene Therapeutics is advancing its investigational AlloCAR T products as it seeks to redefine the CAR T cell therapy landscape. The company highlights the potential of allogeneic, or ...
Allogene Therapeutics targets 1 in 3 LBCL relapses with ALPHA3 trial and MRD testing
Allogene Therapeutics is addressing the significant challenge of relapse in large B-cell lymphoma (LBCL), where approximately one in three patients experience cancer recurrence following ...
Allogene Therapeutics reviews investigational cema-cel use and early ALPHA3 safety data for community outpatients
Allogene Therapeutics draws attention to a key discussion by Targeted Oncology and Dr. Jeff Sharman on early safety findings for its ALPHA3 investigational therapy. The conversation also examines ...
Allogene Therapeutics to present pipeline and strategy update at Jefferies Global Healthcare Conference
Allogene Therapeutics is set to participate in the Jefferies Global Healthcare Conference in New York, where the company will provide an update on its investigational pipeline and corporate ...
Allogene Therapeutics leadership to share new clinical and corporate insights at oncology summit
Allogene Therapeutics is set to participate in the upcoming TD Cowen 7th Annual Oncology Innovation Summit, where its leadership team will provide updates on the company pipeline and corporate ...
Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment
Allogene Therapeutics is advancing its research into allogeneic CAR T therapies through its ALPHA3 clinical trial, focusing on new treatment options for patients with large B-cell lymphoma (LBCL). ...
Allogene Therapeutics unveils ALLO-329 with Dagger technology for next generation cell therapy
Allogene Therapeutics has introduced ALLO-329, an investigational allogeneic CAR T cell therapy designed for autoimmune disease treatment. The therapy leverages proprietary Dagger technology, ...
